Skip to content
BiologicalX

Comparison

Modafinil vs Semaglutide

Side-by-side of Modafinil and Semaglutide. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Modafinil

  • FDA approved in 1998 for narcolepsy, with later additions for shift-work sleep disorder and OSA residual sleepiness
  • Schedule IV controlled substance in the US; prescription-only in EU, UK, Australia
  • Increases wakefulness via weak dopamine reuptake inhibition plus histaminergic, noradrenergic, and orexinergic activation
  • Long half-life of 12 to 15 hours requires morning dosing to avoid sleep disruption
  • Modest cognitive enhancement signal in non-sleep-deprived adults at 100 to 200 mg (Battleday meta-review 2015)
  • Substantial CYP3A4 induction reduces hormonal contraceptive efficacy; barrier methods recommended

Semaglutide

  • Long-acting GLP-1 receptor agonist with a ~7-day half-life that supports once-weekly subcutaneous dosing
  • STEP trials reported ~15 to 17% mean body-weight loss at 2.4 mg/week over 68 weeks in adults with obesity
  • Lowers HbA1c by ~1.0 to 1.8 percentage points in type 2 diabetes versus placebo
  • SELECT trial showed reduced major cardiovascular events in adults with prior CVD and overweight or obesity
  • Up to 25 to 40% of weight lost can be lean mass; pairing with resistance training and protein intake mitigates this
  • GI effects (nausea, vomiting, constipation) drive most discontinuations and ease with slow titration

Side-by-side

Attribute Modafinil Semaglutide
Category pharmaceutical pharmaceutical
Also known as Provigil, Modalert, Modvigil, diphenylmethylsulfinyl-acetamide Ozempic, Wegovy, Rybelsus
Half-life (hr) 13 168
Typical dose (mg) 200 2.4
Dosing frequency daily, morning weekly (SC); daily (oral Rybelsus)
Routes oral subcutaneous, oral
Onset (hr) 1 24
Peak (hr) 3 72
Molecular weight 273.35 4113.58
Molecular formula C15H15NO2S -
Mechanism Weak dopamine reuptake inhibition plus downstream activation of histaminergic, noradrenergic, and orexinergic wake-promoting systems. Long-acting GLP-1 receptor agonist; potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic satiety centers.
Legal status Schedule IV (US); prescription-only globally; not a supplement Prescription only (FDA-approved, EMA-approved)
WADA status banned allowed
DEA / Rx Schedule IV Rx only (not a controlled substance); FDA-approved for type 2 diabetes (2017) and chronic weight management (2021)
Pregnancy Not recommended Not recommended; discontinue 2 months before planned pregnancy
CAS 68693-11-8 910463-68-2
PubChem CID 4236 56843331
Wikidata Q422968 Q27089394

Safety profile

Modafinil

Common side effects

  • headache
  • nausea
  • anxiety
  • insomnia (with late-day dosing)
  • dry mouth
  • mild blood pressure elevation

Contraindications

  • recent myocardial infarction
  • unstable angina
  • left ventricular hypertrophy
  • significant arrhythmia
  • history of Stevens-Johnson syndrome
  • psychotic disorders
  • pregnancy
  • concurrent MAOI use

Interactions

  • hormonal contraceptives: CYP3A4 induction reduces contraceptive efficacy; use barrier method(major)
  • cyclosporine: reduced cyclosporine levels via CYP3A4 induction(major)
  • warfarin: CYP2C9 inhibition raises INR(moderate)
  • phenytoin: CYP2C19 inhibition raises phenytoin levels(moderate)
  • MAOIs: potential hypertensive reaction(major)
  • classical stimulants (amphetamine, methylphenidate): additive cardiovascular and sleep-disruption effects(moderate)

Semaglutide

Common side effects

  • nausea
  • vomiting
  • diarrhea
  • constipation
  • decreased appetite
  • injection-site reactions
  • fatigue

Contraindications

  • personal or family history of medullary thyroid carcinoma
  • multiple endocrine neoplasia type 2
  • pregnancy
  • history of pancreatitis (use caution)

Interactions

  • insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
  • sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
  • oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
  • warfarin: monitor INR due to altered absorption(moderate)

Which Should You Take?

Modafinil comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. Semaglutide is the right call when one of the conditionals below applies.

  • If your priority is wakefulness, pick Modafinil.
  • If your priority is focus or working memory, pick Modafinil.
  • If your priority is metabolic health and glucose control, pick Semaglutide.
  • If your priority is fat loss, pick Semaglutide.

Edge case: Half-lives differ materially (Modafinil ~13 hr vs Semaglutide ~168 hr). Semaglutide reaches steady state faster; Modafinil is easier to dial in if tolerability is uncertain.

Default choice: Modafinil. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Semaglutide only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Modafinil and Semaglutide?

Modafinil and Semaglutide differ in category (pharmaceutical vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Modafinil or Semaglutide?

Modafinil half-life is 13 hours; Semaglutide half-life is 168 hours.

Can you stack Modafinil with Semaglutide?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper